This article is part of the supplement: Optimizing the use of carbapenems in the face of increasing Gram-negative resistance
The role of carbapenems in initial therapy for serious Gram-negative infections
-
Correspondence: James J Rahal JJR9002@nyp.org
Critical Care 2008, 12(Suppl 4):S5 doi:10.1186/cc6821
Accesses
- Last 30 days: 75 accesses
- Last 365 days: 1167 accesses
- All time: 7846 accesses